What do systematic reviews say?

Selective serotonin reuptake inhibitors vs placebo

SSRI probably leads to higher participant distress about PE compared with placebo (moderate certainty).

• Selective serotonin re‐uptake inhibitors for premature ejaculation in adult men 2021 · Cochrane Headline outcomes only
  RR 1.54 [1.26, 1.88]
  1 study · 652 participants
  Moderate

Selective serotonin reuptake inhibitors vs placebo

SSRI probably leads to higher adverse events compared with placebo (moderate certainty).

• Selective serotonin re‐uptake inhibitors for premature ejaculation in adult men 2021 · Cochrane Headline outcomes only
  RR 1.71 [1.48, 1.99]
  17 studies · 4624 participants
  Moderate

Selective serotonin reuptake inhibitors vs placebo

• Selective serotonin re‐uptake inhibitors for premature ejaculation in adult men 2021 · Cochrane Headline outcomes only
  no estimate extracted
  20 studies · 5872 participants
  Low

Noradrenaline reuptake inhibitors vs placebo

It is very uncertain whether noradrenaline reuptake inhibitors changes mental state: significant response or improvement in negative… compared with placebo (very low certainty).

• Selective noradrenaline reuptake inhibitors for schizophrenia 2018 · Cochrane Headline outcomes only
  RR 3.17 [1.52, 6.58]
  1 study · 50 participants
  Very low

Noradrenaline reuptake inhibitors vs placebo

• Selective noradrenaline reuptake inhibitors for schizophrenia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 294 participants
  Low

Noradrenaline reuptake inhibitors vs placebo

It is very uncertain whether noradrenaline reuptake inhibitors changes clinical global response: significant response or improvement in… compared with placebo (very low certainty).

• Selective noradrenaline reuptake inhibitors for schizophrenia 2018 · Cochrane Headline outcomes only
  RR 0.99 [0.45, 2.2]
  1 study · 28 participants
  Very low

Noradrenaline reuptake inhibitors vs placebo

The review found no eligible studies for this question.

• Selective noradrenaline reuptake inhibitors for schizophrenia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Noradrenaline reuptake inhibitors vs placebo

• Selective noradrenaline reuptake inhibitors for schizophrenia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 180 participants
  Low

Noradrenaline reuptake inhibitors vs placebo

• Selective noradrenaline reuptake inhibitors for schizophrenia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 114 participants
  Very low

Noradrenaline reuptake inhibitors vs placebo

Noradrenaline reuptake inhibitors showed no clear difference in adverse effects: Nausea ‐ short term (2 to 12 weeks) compared with placebo (low certainty).

• Selective noradrenaline reuptake inhibitors for schizophrenia 2018 · Cochrane Headline outcomes only
  RR 0.49 [0.1, 2.41]
  3 studies · 176 participants
  Low

SPRM vs placebo

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 171 participants
  Moderate

SPRM vs leuprolide acetate

SPRM showed no clear difference in abnormal uterine bleeding: amenorrhoea compared with leuprolide acetate (moderate certainty).

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  OR 1.14 [0.6, 2.16]
  1 study · 280 participants
  Moderate

SPRM vs leuprolide acetate

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 281 participants
  Moderate

SPRM vs leuprolide acetate

SPRM probably leads to higher adverse effects: SPRM‐associated endometrial changes compared with leuprolide acetate (moderate certainty).

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  OR 10.45 [5.38, 20.33]
  1 study · 301 participants
  Moderate

SPRM vs placebo

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 200 participants
  Moderate

SPRM vs placebo

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 310 participants
  Moderate

SPRM vs placebo

SPRM probably leads to higher abnormal uterine bleeding: amenorrhoea compared with placebo (moderate certainty).

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  OR 82.5 [37.1, 183.9]
  7 studies · 590 participants
  Moderate

SPRM vs placebo

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 629 participants
  GRADE not reported

SPRM vs placebo

SPRM may leads to higher adverse effects: SPRM‐associated endometrial changes compared with placebo (low certainty).

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  OR 15.12 [6.45, 35.47]
  5 studies · 405 participants
  Low

SPRM vs leuprolide acetate

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 281 participants
  Moderate